| Date Filed | Type | Description |
| 08/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
| 04/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/14/2023 |
SC 13G/A
| Auctus Fund Management LLC reports a 9.9% stake in BioRestorative Therapies, Inc. |
| 02/13/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 02/07/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/07/2023 |
SC 13G/A
| Hudson Bay Capital Management LP reports a 0% stake in BioRestorative Therapies, Inc. |
| 01/05/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/05/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/30/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 09/23/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Amendments to Articles of Incorpor... |
| 08/16/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/14/2022 |
SC 13G
| Auctus Fund Management LLC reports a 5.8% stake in BioRestorative Therapies, Inc. |
| 06/23/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/21/2022 |
SC 13D/A
| Broadrick Dale reports a 16.8% stake in BioRestorative Therapies, Inc. |
| 06/17/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/18/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/07/2022 |
SC 13D/A
| Broadrick Dale reports a 15.7% stake in BioRestorative Therapies, Inc. |
| 03/29/2022 |
SC 13D/A
| Broadrick Dale reports a 14.6% stake in BioRestorative Therapies, Inc. |
| 02/14/2022 |
SC 13G/A
| Altium Capital Management LP reports a 5% stake in BioRestorative Therapies, Inc. |
| 02/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/04/2022 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 5% stake in BioRestorative Therapies, Inc., |
|